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Novelty statement: Tumor infiltrating lymphocyte (TIL) expressing checkpoint molecules 
show significant variation in testicular diffuse large B-cell lymphoma (T-DLBCL). Despite the 
overall favorable impact of high TIL content on survival of the patients with T-DLBCL, the 
presence of T-regulatory cells, and more specifically T-bet⁺ Tregs  identify a subgroup of 
patients with a poor outcome. The findings emphasize the important role of the tumor 
microenvironment and checkpoint molecules in regulating survival and 
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Abstract
Objectives: Testicular diffuse large B-cell lymphoma (T-DLBCL) is a rare and aggressive 
extranodal lymphoma. We have previously shown that high content of tumor-infiltrating 
lymphocytes (TILs) and PD-1 expressing TILs associate with better survival in T-DLBCL. In 
this study, we have further characterized distinct TIL subtypes and their proportions in 
association with patient demographics and survival. 
Methods: We used multiplex immunohistochemistry (mIHC) to characterize TIL phenotypes, 
including cytotoxic T-cells (CTLs) (CD8⁺, OX40⁺, Granzyme B⁺, Ki-67+, LAG-3⁺, TIM-3⁺, PD-
1⁺), CD4+ T-cells (CD3+, CD4+, TIM-3+, LAG-3+), regulatory T-cells (Tregs; CD3+, CD4+, 
FoxP3+), and T helper 1 cells (Th1; CD3+, CD4+, T-bet+) in 79 T-DLBCLs, and correlated the 
findings with patient demographics and outcome. 
Results: We observed a substantial variation in TIL phenotypes between the patients. The 
most prominent CD8+ TILs were Ki-67+ and TIM-3+ CTLs, whereas the most prominent CD4+ 
TILs were FoxP3⁺ Tregs. Despite the overall favorable prognostic impact of high TIL content, 
we found a subpopulation of T-bet⁺FoxP3+ Tregs that had a significant adverse impact on 
survival. Lower content of CTLs with activated or exhausted phenotypes correlated with 
aggressive clinical features.
Conclusions: Our results demonstrate significant variation in TIL phenotypes and 
emphasize the adverse prognostic impact of Tregs in T-DLBCL. 
Keywords: Tumor-infiltrating lymphocyte, regulatory T-cell, lymphoma, testicular diffuse 
large B-cell lymphoma
Introduction
Primary testicular lymphoma (PTL) is a unique subtype of extranodal lymphomas most often 
representing non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma 
(DLBCL). It has an aggressive clinical behavior and a tendency to relapse in the 
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Tumor microenvironment (TME) in B-cell lymphomas consists of several different immune 
cell subpopulations, including tumor-infiltrating lymphocytes (TILs), tumor-associated 
macrophages (TAMs), natural killer (NK) cells, and dendritic cells, in addition to blood 
vessels and extracellular matrix (6). TILs are a heterogenous group of T-cells with different 
functions and complex regulatory pathways. Cytotoxic CD8+ T-lymphocytes (CTLs) are 
crucial in cell-mediated antitumor immune response, whereas CD4⁺ TILs include several 
different subtypes such as T helper (Th) cells and regulatory T-cells (Tregs).
A normally functioning immune system requires both activation of immune cells as well as 
regulatory mechanisms that downregulate the immune response, and excessive immune 
activation against pathogens and self-antigens can lead to serious autoimmune diseases. Th 
cells are immune cells that are essential in adaptive immune response and can be further 
divided into distinct subgroups such as T helper 1 (Th1) cells and T helper 2 (Th2) cells, 
whereas Tregs are one of the crucial regulatory immune cells that induce self-tolerance by 
suppressing the host immune response against self-antigens and tumors (7-10).
Cancer cells have several mechanisms of escaping the host immune response (6, 11-14). 
Interactions between cancer cells and host immune cells can alter the surface molecule 
expression on both tumor and host immune cells and lead to changes in the function and 
activity of the cells. Induced expression of immune checkpoint molecules programmed cell 
death protein 1 (PD-1), T-cell immunoglobulin mucin 3 (TIM-3), and lymphocyte-activation 
gene 3 (LAG-3) on TILs can lead to T-cell exhaustion but can also indicate T-cell receptor 
(TCR) activation or differentiation of CD4⁺ TILs into a subset of T follicular helper (Tfh) cells 
(15-19). Additionally, interactions in the TME can shift the balance of CD4⁺ TIL differentiation 
from Th cells towards immunosuppressive Tregs (6).
Previous genome-wide, gene expression and immunohistochemical studies have led to a 
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lymphoma (T-DLBCL) (4, 5, 20-27). It has previously been shown that high PD-L1 protein 
and gene expression as well as high overall TIL and PD-1⁺ TIL contents translate to better 
survival of T-DLBCL patients (22). Additionally, a T-lymphocyte signature has been 
described to separate T-DLBCL patients with different outcomes so that the patients with 
high expression of the T-lymphocyte signature were reported to have better outcome (23). 
Here, we have further characterized distinct TIL subpopulations in T-DLBCL and correlated 
the findings with clinical and biological characteristics and survival.
Materials and Methods
Patients
We searched the pathology databases of three University hospitals in Southern Finland and 
found 79 patients diagnosed with T-DLBCL between years 1987 and 2013. Clinical data 
were collected from patient files and histological diagnosis was established from surgical 
pretreatment tumor tissue according to current criteria of the World Health Organization 
(WHO) classification (28). Cell-of-origin (COO) was defined according to the Hans algorithm 
by experienced hematopathologists (29, 30). The protocol and sampling were approved by 
the Institutional Review Boards, Ethics Committees, and the Finnish National Supervisory 
Authority for
Welfare and Health. Due to the retrospective nature of the study, no informed consent was 
needed or obtained from the patients as the study did not have any effect on the diagnostics, 
treatments, or follow up of the patients.
Multiplex immunohistochemistry (mIHC)
Multiplex immunohistochemistry was performed as described previously (22). Formalin-fixed 
paraffin-embedded (FFPE) primary tissue samples were collected from the local biobanks 
and a tissue microarray (TMA) was constructed. The cores on the TMA were selected by a 
hematopathologist and the diagnoses were revised to meet with the current criteria of the 
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panels (panel 1: CD3, CD4, FoxP3, T-box expressed in T-cells (T-bet); panel 2: CD3, CD4, 
LAG-3, TIM-3; panel 3: CD8, OX40, Granzyme B (GrB), Ki-67; panel 4: CD8, LAG-3, TIM-3, 
PD-1; Supplementary Table S1) followed by fluorescently labeled secondary antibodies and 
DAPI counterstain (nuclear stain). Fluorescent images were captured with Axio Imager.Z2 
(Zeiss, Germany) and intensity measurements (upper quartile intensity), cell segmentation, 
and immune cell classification were performed using CellProfiler 2.2.0 (31). Different 
immune cell subtypes were quantified as proportions to all cells (e.g. CD3⁺ indicating the 
number of CD3⁺ cells form all cells in a TMA spot) or as proportions to distinct immune cells 
(e.g. T-bet⁺CD3⁺/CD3⁺ implying the proportion of T-bet⁺CD3⁺ double-positive cells from all 
CD3⁺ cells). Data from two spots of the same patient were combined. Data of distinct T-
lymphocyte subtypes were merged in case the same subpopulation was studied in two 
panels (e.g. the proportion of CD3⁺ cells in panels 1 and 2). A more detailed description of 
the staining is provided in the Supplementary methods.
Gene expression analysis
Gene expression levels of IFNG and ICOS were measured from 60 samples using digital 
gene expression analysis with NanoString nCounter (NanoString Technologies, Seattle, WA, 
USA) (23).
Survival definitions and statistical analysis
Overall survival (OS) was defined as the time between diagnosis and death from any cause, 
disease specific survival (DSS) as the time between diagnosis and death due to T-DLBCL, 
and progression free survival (PFS) as the time between diagnosis and T-DLBCL 
progression or death from any cause. IBM SPSS v24.0 (IBM, Armonk, NY, USA) was used 
to conduct statistical analysis. For hierarchical clustering, the data were z-score transformed, 
and clustering was done with the JExpress Pro 2012 software (32) using cosine correlation 
distance measure with average linkage. The possible association of different clusters with 
the baseline patient characteristics were assessed using the Chi square test. The 
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among patient groups with different risk factors were analyzed by Mann-Whitney U test. 
Univariate and multivariate analyses were performed according to the Cox proportional 
hazards regression model, and survival rates were estimated using the Kaplan-Meier 




Median age at diagnosis was 70 years (range 37-92 years), and majority of the cases 
represented non-GCB phenotype. Majority of the patients (82%) were treated with 
anthracycline-based chemotherapy, and approximately half of the patients had received 
CNS-targeted therapy and rituximab as a part of their treatment. The contralateral testis was 
treated in 29% of the patients. The baseline and treatment characteristics are summarized in 
Table 1. Median follow-up time was 46 months (range 0-120 months). Altogether, we 
observed 38 deaths, 27 lymphoma deaths, and 42 lymphoma progressions translating to 
five-year OS, DSS, and PFS rates of 54%, 60%, and 46%, respectively.
Clusters of different TIL immunophenotypes
To characterize the different TIL subpopulations, their phenotypes and distributions in T-
DLBCL, we analyzed TIL phenotypes by mIHC from primary tumor samples (Figure 1A). 
Tregs and Th1 cells were characterized by using antibodies for CD3, CD4, FoxP3, and T-
bet. The expression of immune checkpoint molecules LAG-3, TIM-3, and PD-1 were studied 
on CD4⁺ T-cells and CD8+ CTLs to detect TILs with a potential exhausted phenotype, 
whereas antibodies against OX40, GrB, and Ki-67 were used to detect CTLs with a potential 
activated phenotype.
We observed a great variation in the contents of the distinct TIL subpopulations between 
different patients (Figure 1B and Supplementary Table S2). The most prominent phenotype 
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second most common FoxP3⁺ (median 2.7%, range 0.2%-16.4%). The most dominant 
phenotype among CD4⁺ TILs was FoxP3⁺ (median 10.8%, range 0.0%-50.3%), and the 
second most dominant TIM-3⁺ (median 6.5%, range 0.1%-36.2%). Most common CTL 
phenotypes were Ki-67+, TIM-3⁺, and PD-1⁺ (median 22.2%, 3.6%, and 2.6%; range 4.7-
85.6%, 0.5%-36.2%, and 0.0%-27.3%, respectively). The median proportions of GrB⁺ and 
Ki-67⁺ CTLs were 2.5% and 22.2% (range 0.0%-25.3% and 4.7%-85.6%, respectively).
When LAG-3⁺ and TIM-3⁺ TILs were combined, the median proportion of these immune 
checkpoint molecule expressing TILs from all TILs was 5.1% (range 0.0%-31.9%) and the 
median proportion of immune checkpoint molecule expressing CD4⁺ TILs from all CD4⁺ TILs 
6.5% (range 0.0%-36.2%). Adding PD-1⁺ cells to this, the median proportion of immune 
checkpoint molecule expressing CTLs from all CTLs was 7.5% (range 0.0%-36.2%).
Next, we performed unsupervised hierarchical clustering and observed that the proportions 
of different TIL phenotypes clearly separated two patient groups with different cell 
populations (Figure 1C). The patients in group A (n=22) had altogether higher proportions of 
different TIL subtypes (CD3⁺ TILs, Tregs, Th1 cells, and CTLs), as well as generally higher 
proportions of TILs with expression of activation or exhaustion markers, as compared to the 
patients in group B (n=57) (Figure 1A). A subcluster of TILs with high expression of immune 
checkpoint molecules (LAG-3+, TIM-3+, and PD-1+) also clearly divided the patients into high 
(n=25) and low (n=54) subgroups (Supplementary Figure S1A). Additionally, other smaller 
subclusters representing cytotoxic activity, TIL proliferation, and Tregs could be observed 
(Supplementary Figure S1B-D).
Association of TIL phenotypes with clinical risk factors and disease characteristics
The association of TIL phenotype subgroups with clinical and biological risk factors is shown 
in Supplementary Table S3. When the patients were divided into high (higher expression) 
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differences were found in clinical and biological risk factors between the high and low 
subgroups (Supplementary Table S3). 
We also analyzed the association of individual TIL phenotypes with clinical and biological 
risk factors (Figure 2). We found higher proportions of TILs, particularly activated CTLs, 
among patients with non-GCB phenotype. The proportion of CD4⁺ TILs was higher among 
patients with limited stage disease. Lower content of activated and immune checkpoint 
molecule expressing CTLs were observed among patients with B-symptoms, and lower 
content of activated CTLs among patients with advanced stage disease. The proportion of 
Th1 TILs was higher among patients with elevated lactate dehydrogenase (LDH). In 
addition, age over 60 years associated with higher content of immune checkpoint molecule 
expressing TILs in general, as well as immune checkpoint molecule expressing CD4⁺ TILs, 
lower content of Th1 cells, and higher content of activated CTLs. Other baseline clinical or 
biological risk factors did not correlate with distinct TIL phenotypes.
Association of different TIL phenotype clusters and the proportion of Tregs with patient 
survival
Patients with higher proportions of all studied TIL phenotypes combined had significantly 
longer OS, DSS, and PFS than patients with lower proportions of the TIL phenotypes (high 
vs. low subgroups in TIL cluster, respectively, Figure 1C and Supplementary Figure S2A-C), 
reflecting the previously observed favorable impact of CD4+ and CD8+ TILs on patient 
outcome (22, 23). The subclusters representing high immune checkpoint molecule 
expression, cytotoxic activity, TIL proliferation, and Tregs (Supplementary Figure S1A-D) did 
not correlate with patient survival (data not shown).
The survival association of distinct TIL phenotypes and clinical risk factors are shown in 
Figure 3. As described earlier, higher proportion of all CD3+ TILs and higher proportion of 
CD8+ CTLs correlated with favorable survival (Figure 3 and Supplementary Figure S3). In 
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patient outcome. This association was significant in multivariate analysis with the 
International Prognostic Index (IPI) as well as with the proportions of CD3⁺ and CD4⁺ TILs 
(Table 2). The Kaplan-Meier estimates are presented in Figure 4 (A-C). Higher content of all 
T-bet⁺ TILs also associated with significantly shorter survival, independent of the IPI and the 
proportion of CD3⁺ and CD4⁺ TILs (Supplementary Table S4, Supplementary Figure 4A-C). 
The proportion of FoxP3⁻T-bet⁺ TILs did not, however, correlate with survival (OS, p=0.132; 
DSS, p=0.088; PFS, p=0.216), further suggesting that the association with survival is 
specifically related to the proportion of FoxP3⁺T-bet⁺ double positive Tregs. None of the 
other studied TIL phenotypes had significant correlation with survival (Figure 3 and 
Supplementary Figure S3).
To determine whether the TIL phenotypes associated with T-cell dysfunction, we compared 
the expression of T-cell activation markers ICOS and IFNG between different TIL subsets 
(Supplementary Table S5). The expression of ICOS correlated positively with the content of 
TILs with double-expression of FoxP3 and T-bet. Interestingly, the expression levels of T-cell 
activation markers ICOS and IFNG also correlated positively with the expression of immune 
checkpoint molecules.
Discussion
It is well established that the distribution and clinical impact of different TIL subpopulations 
can vary substantially in lymphomas including T-DLBCLs (22, 23, 26, 33-35). It has recently 
been shown that high CD4+ and CD8+ TIL contents translate to favorable survival in patients 
with T-DLBCL (22, 23). In the current study, our aim was to further characterize the 
phenotypes, distributions, and clinical impact of different TILs in T-DLBCL. We observed a 
substantial variation in the content of distinct TIL subpopulations between the patients. 
Despite the overall favorable prognostic impact of high TIL content, the presence of 
FoxP3+T-bet⁺ TILs identified a subgroup of patients with a poor outcome. Altogether, a 
relatively small proportion of all TILs, CD4⁺ TILs, and CTLs expressing immune checkpoint 
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LAG-3 nor TIM-3 on TILs alone had significant impact on survival, higher content of CD4+ 
TILs with combined expression of LAG-3 and TIM-3 tended to have adverse prognostic 
impact. 
CD4⁺ T-cells are divided into several subgroups, including Tregs and Th cells (36). In the 
TME, FoxP3⁺ Tregs have an immune suppressive role, while CD4⁺ Th cells are responsible 
for anti-tumor activation of CTLs, and can also cause direct elimination of the tumor cells 
(37-41). In our study, a marked proportion of CD4⁺ TILs was found to represent FoxP3⁺ 
Tregs. While the proportion of all FoxP3⁺ Tregs from CD4⁺ TILs did not have any impact on 
survival, T-bet⁺CD4+ TILs, and particularly T-bet+FoxP3+ TILs translated to poor outcome, 
both independent of IPI. Considering that T-bet is a master regulator of Th1 cell lineage 
commitment and Th1 specific expression of IFN the finding was initially unexpected (42). 
However, as the content of FoxP3⁻T-bet⁺ TILs did not correlate with survival, we can 
conclude that the adverse prognostic impact of T-bet positivity is due to T-bet expression in 
T-bet+FoxP3+ Tregs.
FoxP3+T-bet+ T-cells are a subpopulation of Tregs, and ICOS is a well recognized Treg 
activation marker described important in the pathogenesis of some lymphomas such as 
follicular lymphoma (FL) (36, 42-45). In this study, we observed a significantly higher 
expression levels of ICOS in T-DLBCLs with FoxP3+T-bet+ Tregs, further suggesting a 
significant adverse prognostic impact of a subgroup of activated FoxP3+T-bet+ Tregs in T-
DLBCL. Another recently published study on DLBCL described different subtypes of Tregs, 
such as follicular regulatory T (Tfr) cells and non-Tfr Tregs, that were involved in the 
intratumoral immunity with different functional roles and distinct effects on tumor cell 
proliferation (46). Our results are in line with these findings and emphasize the request for 
further studies to characterize the functional role and regulation of different Treg subtypes in 
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T-DLBCL has been characterized among the few lymphoma entities that harbor genetic and 
immunologic features such as frequent alterations in 9p24.1, recurrent rearrangements of 
CIITA and FOXP1, and loss of HLA class I and II expression that may predict sensitivity to 
immune checkpoint blockade (23, 27, 47). Interestingly, preliminary results on the use of 
immune checkpoint inhibitors in relapsed/refractory T-DLBCL have been promising (48). 
However, a more detailed mechanistic studies as well as clinical trials are needed to 
examine the function of immune checkpoint molecules and the role of immune checkpoint 
blockade in T-DLBCL. 
We observed that gene expression levels of T-cell activation markers ICOS and IFNG 
correlated positively with the expression of immune checkpoint molecules. The findings 
suggest that TILs that express immune checkpoint molecules represent a heterogeneous 
population of both activated and exhausted TILs, most likely depending on their TME niche. 
In line with our findings are the recently published data from a mouse tumor model showing 
that CD8⁺ TILs with a co-expression of inhibitory immune checkpoint receptors are highly 
activated and functional (19). 
In conclusion, we have identified a subpopulation of FoxP3+T-bet⁺ Tregs that associate with 
poor outcome of patients with T-DLBCL and correlate with the expression of Treg activation 
marker ICOS. In other lymphoma subtypes such as FL, the ICOS-pathway has been shown 
to be significant in lymphoma pathogenesis, and clinical trials with immunotherapy targeting 
the ICOS-pathway are ongoing. According to the findings of our current study, ICOS-
pathway targeted drugs might be a promising new therapy approach also for treating 
patients with T-DLBCL. However, the results of our study are preliminary, and further studies 
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Tables
Table 1. Patient characteristics.
Characteristics number (%)
Number of patients 79
Median age (range) 70 (37-92)
Age
 ≤60, years 18 (23)






 I-II 49 (62)
 III-IV 27 (34)
Elevated LDH† 25 (32)
>1 extranodal lesion at diagnose 17 (22)
CNS involvement at diagnose 2 (3)




 0-2 52 (66)







CNS prophylaxis 37 (47)
 IV prophylaxis 34 (43)
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Anthracycline based chemotherapy 65 (82)
Treated with rituximab 36 (46)
Contralateral testis treated‡ 23 (29)
Relapses 28 (35)
Deaths 38 (48)
 Lymphoma-specific 27 (34)
 Other 11 (14)
† LDH, lactate dehydrogenase; ‡Contralateral testis treated either with surgery (n=11) or irradiation (n=12); CNS, central 
nervous system; IPI, international prognostic index; GCB, germinal center B-cell like; nd, not determined; IV, intravenous; 
IT, intrathecal.





HR 95% CI p
DSS
HR 95% CI p
PFS




1.533 1.08-2.18 0.018 1.474 1.04-2.10 0.032 1.474 1.05-2.07 0.025




1.666 1.19-2.33 0.003 1.761 1.24-2.50 0.002 1.561 1.13-2.16 0.007
CD3⁺ 0.956 0.92-1.00 0.027 0.942 0.89-0.99 0.028 0.964 0.93-1.00 0.045




1.664 1.16-2.40 0.006 1.655 1.13-2.42 0.009 1.581 1.12-2.23 0.009
IPI 3-5 4.559 2.22-9.36 <0.001 9.679 3.78-24.80 <0.001 4.029 2.04-7.97 <0.001
CD3⁺ 0.953 0.92-0.99 0.023 0.939 0.89-0.99 0.028 0.959 0.93-0.99 0.021
CD4⁺ 0.998 0.87-1.13 0.862 0.966 0.79-1.18 0.740 1.030 0.94-1.13 0.531
†TIL, tumor-infiltrating lymphocyte; OS, Overall survival; DSS, Disease Specific Survival; PFS, Progression Free Survival; HR, Hazard 
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Figure legends
Figure 1. Characterization and proportions of distinct tumor-infiltrating T-cell (TIL) 
immunophenotypes as well as unsupervised hierarchical clustering of the T-cell 
immunophenotypes based on multiplex immunohistochemistry (mIHC). A) 
Representative mIHC images from the cytotoxic T-lymphocyte (CTL) and CD4⁺ TIL 
immunophenotyping. CD8=cyan, LAG-3=blue, TIM-3=red, PD-1=green, Ki-67=red, 
GrB=green, OX40=blue, dapi=grey; CD3=green, CD4=cyan, LAG-3=blue, TIM-3=red, 
FoxP3=red, T-bet=blue, dapi=grey. B) Box plots visualizing the proportions of distinct CD4+ 
TIL and CTL phenotypes. Ki-67 is shown as a separate box plot due to a different scale.C) A 
heatmap visualizing unsupervised hierarchical clustering of the mIHC data with TIL 
immunophenotypes. Two patient subgroups are indicated with green (high expression) and 
blue (low expression) colors. Selected TIL immunophenotypes are depicted in the right 
panel. 
Figure 2. Association of distinct tumor-infiltrating lymphocyte (TIL) 
immunophenotypes with the clinical and biological risk factors. The possible 
association of TIL immunophenotypes with age at diagnose, performance status, B-
symptoms, stage, lactate dehydrogenase (LDH), number of extranodal lesions, lymphoma 
involvement of the central nervous system (CNS) and contralateral testis at diagnose, 
International Prognostic Index (IPI) score, and molecular subgroup were assessed using 
Mann-Whitney U test. The box plots visualize the associations with p<0.05.
Figure 3. Association of different tumor-infiltrating lymphocyte (TIL) 
immunophenotypes as well as clinical and biological risk factors with overall survival 
(OS) and disease specific survival (DSS) in testicular diffuse large B-cell lymphoma 
(T-DLBCL) patients. A-B) Forest plots with univariate analysis using continuous variables 
showing the association of distinct TIL immunophenotypes with OS (A) and DSS (B) of 
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center; IPI, International Prognostic Index; CNS, central nervous system; IV, intravenous; IT, 
intrathecal.
Figure 4. Association of high FoxP3⁺T-bet⁺ tumor-infiltrating lymphocytes (TILs) with 
worse survival. A-C) Demonstrative Kaplan-Meier curves depict overall survival (OS) (A), 
disease specific survival (DSS) (B), and progression free survival (PFS) (C) differences 
between patients positive or negative for FoxP3⁺T-bet⁺CD3⁺CD4⁺/CD3⁺CD4⁺ TILs. 
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